Abstract
Chronic heart failure (CHF) is common, and increases in incidence and prevalence with age. There are compelling data demonstrating reduced mortality and hospitalizations with adrenergic blockade in older patients with CHF. Despite this, many older patients remain undertreated. The aim of the present article is to review the potential mechanisms of the benefits of adrenergic blockade in CHF and the clinical data available from the large randomized studies, focusing particularly on older patients.
MeSH terms
-
Adrenergic beta-Antagonists / administration & dosage
-
Adrenergic beta-Antagonists / pharmacology
-
Adrenergic beta-Antagonists / therapeutic use*
-
Aged
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Arrhythmias, Cardiac / prevention & control
-
Carbazoles / pharmacology
-
Carbazoles / therapeutic use*
-
Carvedilol
-
Chronic Disease
-
Comorbidity
-
Digoxin / pharmacology
-
Digoxin / therapeutic use
-
Heart Failure / drug therapy
-
Heart Failure / epidemiology
-
Heart Failure / prevention & control*
-
Humans
-
Propanolamines / pharmacology
-
Propanolamines / therapeutic use*
-
Ventricular Dysfunction, Left / epidemiology
-
Ventricular Remodeling / drug effects
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Carbazoles
-
Propanolamines
-
Carvedilol
-
Digoxin